WeTrials
Recruiting

A Phase 1 Study of ASP3082 in Participants With Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation

What is this study?

This clinical trial is testing a new medication called ASP3082 for people with advanced solid tumor cancers that have a specific genetic change known as a KRAS G12D mutation. The main goal is to find out how safe the medicine is and to figure out the best doses to use.

Who can participate?

You might be able to join if you have an advanced or spreading solid tumor with the KRAS G12D mutation and standard treatments are no longer working for you, or if you have untreated metastatic pancreatic cancer. Participants must also be willing to provide tumor tissue samples and meet specific health guidelines.

What will happen?

You will receive the study treatment through a vein as an infusion during cycles that last 21 or 28 days. The study has two parts to test different doses alone or with other medications, and you will continue treatment as long as it helps and you do not experience severe side effects.

Where and when?

This study is currently recruiting participants at multiple locations, including sites in California and Colorado within the United States.

Key Points
  • 1Testing a new drug called ASP3082 for cancers with a KRAS G12D mutation
  • 2Helps researchers find the safest and most effective doses
  • 3Currently recruiting patients at participating medical centers

No related links yet

Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Solid Tumor

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.